India, March 31 -- Shares of Vaxcyte, Inc. (PCVX) tanked over 53% on Monday despite the clinical-stage vaccine company announced positive topline results from from VAX-24 infant phase 2 dose-finding study.
PCVX is currently trading at $32.22, down $37.24 or 53.62%, on the Nasdaq. The stock opened its trading at $33.37 after closing Friday at $69.46. The stock has traded between $31.00 and $121.06 in the past 52-week period.
The Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, the company's 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Prevnar 20 (PCV20) in healthy infants.
googletag.cmd.push(function() { googletag.d...